NRx Pharmaceuticals Receives Positive FDA Review for Ketamine ANDA, Targets 2026 Approval
NRx Pharmaceuticals has received a positive FDA review letter for its ketamine ANDA and reported a supportive meeting with FDA leadership, advancing its preservative-free ketamine product toward potential approval in summer 2026 for treating severe mental illness.
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) announced it received a positive Discipline Review Letter from the FDA Office of Generic Drugs covering quality-related aspects of its ketamine ANDA, with only minor administrative updates requested. The company also reported a supportive meeting with FDA leadership aligned with federal priorities to accelerate treatments for severe mental illness, reinforcing expectations for potential approval of its preservative-free ketamine product in summer 2026.
The development represents a significant step forward for NRx Pharmaceuticals, a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for central nervous system disorders. The company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone), with NRX-100 having received Fast Track Designation for treating suicidal ideation in depression, including bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 with an application for the Commissioner's National Priority Voucher Program for treating suicidal ideation in patients with depression.
The positive FDA review and supportive meeting indicate regulatory alignment with the company's development timeline, potentially bringing a new treatment option to market for severe mental health conditions. This progress comes amid increased focus on mental health treatments and federal initiatives to accelerate development of therapies for serious psychiatric disorders. The company's latest news and updates are available in its newsroom at https://ibn.fm/NRXP.
The announcement was distributed through BioMedWire, a specialized communications platform focused on biotechnology and biomedical sciences developments. BioMedWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN that provides wire solutions, article syndication, press release enhancement, and social media distribution. For more information about BioMedWire, visit https://www.BioMedWire.com.